Primary malignant melanoma of the esophagus (PMME) is an exceedingly rare disease with a poor prognosis. The etiology of PMME remains largely unknown and genetic characteristics are yet to be clarified, essential for identifying potential therapeutic targets and defining treatment guidelines. Here, we performed whole-exome sequencing on 47 formalin-fixed paraffin-embedded specimens from 18 patients with PMME, including 23 tumor samples, 6 metastatic lymph nodes, and 18 tumor-adjacent normal tissues. The genomic features of PMME were comprehensively characterized, and comparative genomic analysis was further performed between these specimens and 398 skin cutaneous melanomas (SKCM), 67 non-esophagus mucosal melanomas (NEMM), and 79 uveal melanomas (UVM). In the PMME cohort, recurrently mutated driver genes, such as MUC16, RANBP2, NRAS, TP53, PTPRT, NF1, MUC4, KMT2C, and BRAF, were identified. All RANBP2 mutations were putatively deleterious, and most affected samples had multipoint mutations. Furthermore, RANBP2 showed parallel evolution by multiregional analysis. Whole-genome doubling was an early truncal event that occurred before most driver mutations, except for in TP53. An ultraviolet radiation-related mutational signature, SBS38, was identified as specific to epithelial melanomas and could predict inferior survival outcomes in both PMME and SKCM patients. Comparing the mutational and copy number landscapes between PMME and other subtypes of melanoma revealed that PMME has a similar genomic pattern and biological characteristics to SKCM. In summary, we comprehensively defined the key genomic aberrations and mutational processes driving PMME and suggested for the first time that PMME may share similar genomic patterns with SKCM; therefore, patients with rare melanomas, such as PMME, may benefit from the current treatment used for common cutaneous melanoma.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The sequence reported in this paper has been deposited in the CNGBdb (China National GeneBank database, https://www.cngb.org) under accession number CNP0001947. The remaining data are available within the supplementary files or from the authors upon request.
Wallis, G., Sehgal, V., Haider, A., Bridgewater, J., Novelli, M., Dawas, K. et al. Primary malignant melanoma of the esophagus. Endoscopy 47 Suppl 1 UCTN, E81–82 (2015).
Spencer, K. R. & Mehnert, J. M. Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treat Res 167, 295–320 (2016).
Lasota, J., Kowalik, A., Felisiak-Golabek, A., Zieba, S., Waloszczyk, P., Masiuk, M. et al. Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors. Mod Pathol 32, 957–966 (2019).
Tsuyama, S., Kohsaka, S., Hayashi, T., Suehara, Y., Hashimoto, T., Kajiyama, Y. et al. Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus. Histopathology 78, 240–251 (2021).
Bastian, B. C. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9, 239–271 (2014).
Mundra, P. A., Dhomen, N., Rodrigues, M., Mikkelsen, L. H., Cassoux, N., Brooks, K. et al. Ultraviolet radiation drives mutations in a subset of mucosal melanomas. Nat Commun 12, 259 (2021).
Wang, X., Kong, Y., Chi, Z., Sheng, X., Cui, C., Mao, L. et al. Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. Thorac Cancer 10, 950–956 (2019).
Newell, F., Kong, Y., Wilmott, J. S., Johansson, P. A., Ferguson, P. M., Cui, C. et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun 10, 3163 (2019).
Zhou, R., Shi, C., Tao, W., Li, J., Wu, J., Han, Y. et al. Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations. Clin Cancer Res 25, 3548–3560 (2019).
Li, J., Yan, S., Liu, Z., Zhou, Y., Pan, Y., Yuan, W. et al. Multiregional sequencing reveals genomic alterations and clonal dynamics in primary malignant melanoma of the esophagus. Cancer Res 78, 338–347 (2018).
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385 e318 (2018).
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr. & Kinzler, K. W. Cancer genome landscapes. Science (New York, N.Y.) 339, 1546–1558 (2013).
Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Scott Shaffer, J. et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet 51, 1113–1122 (2019).
Bielski, C. M., Zehir, A., Penson, A. V., Donoghue, M. T. A., Chatila, W., Armenia, J. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50, 1189–1195 (2018).
Nahar, R., Zhai, W., Zhang, T., Takano, A., Khng, A. J., Lee, Y. Y. et al. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nat Commun 9, 216 (2018).
Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J. et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol 5, 696–702 (2019).
Cancer Genome Atlas, N. Genomic Classification of Cutaneous Melanoma. Cell 161, 1681–1696 (2015).
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
Newell, F., Wilmott, J. S., Johansson, P. A., Nones, K., Addala, V., Mukhopadhyay, P. et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun 11, 5259 (2020).
Wojtowicz, D., Leiserson, M. D. M., Sharan, R. & Przytycka, T. M. DNA Repair Footprint Uncovers Contribution of DNA Repair Mechanism to Mutational Signatures. Pac Symp Biocomput 25, 262–273 (2020).
Wang, Q., Yang, Y., Yang, M., Li, X. & Chen, K. High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations. Aging (Albany NY) 12, 10827–10843 (2020).
Wang, X., Yu, X., Krauthammer, M., Hugo, W., Duan, C., Kanetsky, P. A. et al. The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev 29, 1792–1799 (2020).
Yang, Y., Zhang, J., Chen, Y., Xu, R., Zhao, Q. & Guo, W. MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan-cancer. Clin Transl Med 10, e155 (2020).
Yu, Y., Lin, D., Li, A., Chen, Y., Ou, Q., Hu, H. et al. Association of immune checkpoint inhibitor therapy with survival in patients with cancers with MUC16 variants. JAMA Netw Open 3, e205837 (2020).
Zhang, L., Han, X. & Shi, Y. Association of MUC16 mutation with response to immune checkpoint inhibitors in solid tumors. JAMA Netw Open 3, e2013201 (2020).
Sekine, S., Nakanishi, Y., Ogawa, R., Kouda, S. & Kanai, Y. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Archiv Int J Pathol 454, 513–517 (2009).
Langer, R., Becker, K., Feith, M., Friess, H., Hofler, H. & Keller, G. Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases. Mod Pathol 24, 495–501 (2011).
Birkeland, E., Zhang, S., Poduval, D., Geisler, J., Nakken, S., Vodak, D. et al. Patterns of genomic evolution in advanced melanoma. Nat Commun 9 (2018).
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880–886 (2015).
Wang, X., El-Halaby, A. A., Zhang, H., Yang, Q., Laughlin, T. S., Rothberg, P. G. et al. p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer. Hum Pathol 68, 22–25 (2017).
Martincorena, I., Fowler, J. C., Wabik, A., Lawson, A. R. J., Abascal, F., Hall, M. W. J. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018).
Yokoyama, A., Kakiuchi, N., Yoshizato, T., Nannya, Y., Suzuki, H., Takeuchi, Y. et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565, 312–317 (2019).
Marin Navarro, A., Pronk, R. J., van der Geest, A. T., Oliynyk, G., Nordgren, A., Arsenian-Henriksson, M. et al. p53 controls genomic stability and temporal differentiation of human neural stem cells and affects neural organization in human brain organoids. Cell Death Dis 11, 52 (2020).
Lopez, S., Lim, E. L., Horswell, S., Haase, K., Huebner, A., Dietzen, M. et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat Genet 52, 283–293 (2020).
McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z. & Swanton, C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 7, 283ra254 (2015).
Navarro, M. S. & Bachant, J. RanBP2: a tumor suppressor with a new twist on TopoII, SUMO, and centromeres. Cancer Cell 13, 293–295 (2008).
Dawlaty, M. M., Malureanu, L., Jeganathan, K. B., Kao, E., Sustmann, C., Tahk, S. et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 133, 103–115 (2008).
Blondel-Tepaz, E., Leverve, M., Sokrat, B., Paradis, J. S., Kosic, M., Saha, K. et al. The RanBP2/RanGAP1-SUMO complex gates beta-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis. Oncogene 40, 2243–2257 (2021).
Curti, B. D. & Faries, M. B. Recent Advances in the Treatment of Melanoma. N Engl J Med 384, 2229–2240 (2021).
Mao, L., Qi, Z., Zhang, L., Guo, J. & Si, L. Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol 12, 680407 (2021).
Lyu, J., Song, Z., Chen, J., Shepard, M. J., Song, H., Ren, G. et al. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. J Pathol 244, 358–366 (2018).
Garutti, M., Targato, G., Buriolla, S., Palmero, L., Minisini, A. M. & Puglisi, F. CDK4/6 inhibitors in melanoma: a comprehensive review. Cells 10 (2021).
We thank all the participants in this study. We would also like to thank Isabella Chao, Diana Hu, Professor Hong Cai and Professor Wenqing Li for their language suggestions.
This study was supported by the National Key R&D Program of China (No. 2018YFC0910700), National Natural Science Foundation of China (81902508, 81972842), Beijing Natural Science Foundation (No. 7192036), Special Fund of Beijing Municipal Administration of Hospitals Clinical Medicine Development (No. XMLX201841) and Beijing Municipal Administration of Hospital’s Ascent Plan (No. DFL20191101).
The authors declare no competing interests.
This study was approved by the Ethics Committee of Peking University Cancer Hospital & Institute (Institutional Review Board No. 2019KT59).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, J., Liu, B., Ye, Q. et al. Comprehensive genomic analysis of primary malignant melanoma of the esophagus reveals similar genetic patterns compared with epithelium-associated melanomas. Mod Pathol (2022). https://doi.org/10.1038/s41379-022-01116-5